drugset / Trial / NCT02619877

Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers

NCT02619877

Phase 2 Completed 59 enrolled Anterogen Co., Ltd.
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a phase II single-blinded study to evaluate the efficacy and safety of ALLO-ASC-DFU in patients with Diabetic Foot Ulcer, compared to standard therapy.

Timeline

Start
2015-10
Primary completion
2016-09
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy Topical

Indications